{"id":"NCT04385368","sponsor":"AstraZeneca","briefTitle":"Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-17","primaryCompletion":"2023-08-31","completion":"2023-08-31","firstPosted":"2020-05-12","resultsPosted":"2024-08-30","lastUpdate":"2024-08-30"},"enrollment":89,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"Durvalumab + SoC chemotherapy","otherNames":["MEDI4736"]},{"type":"OTHER","name":"Placebo + SoC chemotherapy","otherNames":["Placebo"]}],"arms":[{"label":"Durvalumab + SoC chemotherapy","type":"EXPERIMENTAL"},{"label":"Placebo + SoC chemotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery","primaryOutcome":{"measure":"Disease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1])","timeFrame":"Every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months","effectByArm":[{"arm":"Durvalumab + SoC","deltaMin":null,"sd":null},{"arm":"Placebo + SoC","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":140,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Peru","Poland","Romania","Russia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D910LC00001&amp;attachmentIdentifier=827e5769-f8cb-4126-a8b8-dfb578a8506f&amp;fileName=D910LC00001_CSP_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D910LC00001&amp;attachmentIdentifier=5da584de-0a3e-4be1-b55c-7551572c029f&amp;fileName=D910LC00001_SAP_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D910LC00001&amp;attachmentIdentifier=9873843d-d382-419e-b7cd-835f110c0dbc&amp;fileName=D910LC00001_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":45},"commonTop":["Nausea","Constipation","Anaemia","Fatigue","Alopecia"]}}